Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764810 | 1.00 | KMT2A (0.56) | KMT2APPARGPPARAHDAC8SMN1; SMN2 | |
| SCHEMBL28958977 | 0.95 | KMT2A (0.61) | KMT2APPARGPPARASMN1; SMN2RAB9A | |
| SCHEMBL28958978 | 0.95 | KMT2A (0.61) | KMT2APPARGPPARASMN1; SMN2RAB9A | |
| SCHEMBL10021382 | 0.83 | HDAC8 (0.48) | KMT2AHDAC8SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL4426389 | 0.83 | HDAC8 (0.48) | KMT2AHDAC8SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL4426383 | 0.83 | HDAC8 (0.48) | KMT2AHDAC8SMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL6412848 | 0.83 | ALDH1A1 (0.54) | PPARGPPARAHDAC8SMN1; SMN2CYP1A2 | |
| SCHEMBL4434852 | 0.83 | ALDH1A1 (0.54) | KMT2APPARGHDAC8SMN1; SMN2CYP1A2 | |
| SCHEMBL4434849 | 0.83 | ALDH1A1 (0.54) | KMT2APPARGHDAC8SMN1; SMN2CYP1A2 | |
| SCHEMBL6412854 | 0.83 | ALDH1A1 (0.54) | PPARGPPARAHDAC8SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6239288-B1 | RHEUMATIC DISEASES | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | claimed |
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-04-26 | — | — | US | claimed |
| EP-0927156-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998009940-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| WO-2001090361-A2 | MODULATION OF INFLAMMATION BY PROTEASE-TREATED MCP-3 CHEMOKINE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-29 | — | — | WO | disclosed |
| US-6307089-B2 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6239288-B1 | RHEUMATIC DISEASES | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-04-26 | — | — | US | disclosed |
| EP-0927156-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1999021583-A1 | METHOD OF INHIBITING METASTASES OF CANCER CELLS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998009940-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP26, MMP1, MMP9 | KMT2A 4671/4885PPARG 629/4885PPARA 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.